-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Traditional Chinese medicine is a national treasure.
In recent years, it has been supported by a series of favorable national policies.
Especially since 2021, the release of policies such as "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics" has given Chinese medicine a great deal of attention.
Industry brings dividends
.
Not only at the national level, but also at the local level have frequently introduced new policies to support the development of traditional Chinese medicine
.
For example, in January, the "14th Five-Year Plan for High-Quality Development of Traditional Chinese Medicine in Sichuan Province" was released.
The plan has nine chapters and twenty-six sections, and clearly promotes the high-quality development of the traditional Chinese medicine industry
.
Promote the standardized development of the Chinese herbal medicine industry, accelerate the quality and growth rate of the Sichuan pharmaceutical industry, and develop the Chinese medicine health service industry.
The key work is to promote the high-quality development of traditional Chinese medicine
.
The industry predicts that the next three years will be the stage of continuous implementation of traditional Chinese medicine policies
.
In this regard, many institutions believe that benefiting from the successive implementation of policies in the Chinese medicine sector, the Chinese medicine industry will enter high-quality development
.
However, when Chinese medicine is "hot", the agency also reminds the need to calmly and objectively look at the risks faced by its development, such as stricter industry supervision, increased environmental protection requirements, and centralized procurement of proprietary Chinese medicines.
It is recommended to choose a promising subdivision track.
, such as brand Chinese patent medicine OTC, new traditional Chinese medicine, formula granules,
etc.
Branded Chinese patent medicine OTC has independent pricing power
.
In recent years, there has been constant news about the price increase of Chinese herbal medicines, and downstream pharmacies have gradually accepted it, making the OTC price increase channel for proprietary Chinese medicines smooth
.
Everbright Securities said that the implementation of the new national standard will drive production costs to rise sharply.
At the same time, with the continuous price increase of upstream Chinese medicinal materials, it is expected that the industry price increase is expected to be implemented in 2022, and the estimated price increase is 10%-30%
.
From the perspective of corporate gross profit margin, most of the top Chinese patent medicine OTC companies have established their own planting bases, which are less affected by the price increase of upstream Chinese herbal medicines and the control of medical insurance costs.
Ability and terminal premium ability are strong
.
The industry believes that, benefiting from the clearing of industry production capacity and the increase in terminal prices, the advantages of giant companies are prominent, and the industry concentration has increased
.
In recent years, new Chinese medicines have been favored by the acceleration of review and approval, and the speed and number of approvals for marketing have changed a lot
.
The number of innovative traditional Chinese medicine drugs approved in 2021 has reached 12, and in 2022, a new anti-cancer drug, icariin soft capsule, has also been approved for marketing
.
The industry expects that in the next few years, the number of new Chinese medicines approved each year will remain above 10
.
From the perspective of payment, in the medical insurance negotiation in recent years, the proportion of traditional Chinese medicines included in medical insurance has been increasing year by year
.
At the same time, in 2021, the state will also provide guidance on TCM medical institutions and the inclusion of traditional Chinese medicine medical insurance, etc.
, and pointed out that TCM medical institutions may not implement DRG payment for the time being
.
The industry believes that the inflection point of new traditional Chinese medicine drugs has reached, and it is expected to be included in the medical insurance first to achieve heavy volume
.
Compared with traditional decoction pieces, traditional Chinese medicine formula granules have the advantages of convenient taking, convenient carrying and storage,
etc.
The pilot work of traditional Chinese medicine formula granules was officially announced in November 2021, and the ten billion market has ushered in opportunities and challenges.
The industry believes that the future expansion of the traditional Chinese medicine formula market is expected to accelerate, and the filing system and the new national standard will build high industry barriers
.
Without considering the influence of factors such as centralized procurement, it is estimated that the market size of traditional Chinese medicine formula granules will reach 64-108 billion yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In recent years, it has been supported by a series of favorable national policies.
Especially since 2021, the release of policies such as "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics" has given Chinese medicine a great deal of attention.
Industry brings dividends
.
Not only at the national level, but also at the local level have frequently introduced new policies to support the development of traditional Chinese medicine
.
For example, in January, the "14th Five-Year Plan for High-Quality Development of Traditional Chinese Medicine in Sichuan Province" was released.
The plan has nine chapters and twenty-six sections, and clearly promotes the high-quality development of the traditional Chinese medicine industry
.
Promote the standardized development of the Chinese herbal medicine industry, accelerate the quality and growth rate of the Sichuan pharmaceutical industry, and develop the Chinese medicine health service industry.
The key work is to promote the high-quality development of traditional Chinese medicine
.
The industry predicts that the next three years will be the stage of continuous implementation of traditional Chinese medicine policies
.
In this regard, many institutions believe that benefiting from the successive implementation of policies in the Chinese medicine sector, the Chinese medicine industry will enter high-quality development
.
However, when Chinese medicine is "hot", the agency also reminds the need to calmly and objectively look at the risks faced by its development, such as stricter industry supervision, increased environmental protection requirements, and centralized procurement of proprietary Chinese medicines.
It is recommended to choose a promising subdivision track.
, such as brand Chinese patent medicine OTC, new traditional Chinese medicine, formula granules,
etc.
Branded Chinese patent medicine OTC has independent pricing power
.
In recent years, there has been constant news about the price increase of Chinese herbal medicines, and downstream pharmacies have gradually accepted it, making the OTC price increase channel for proprietary Chinese medicines smooth
.
Everbright Securities said that the implementation of the new national standard will drive production costs to rise sharply.
At the same time, with the continuous price increase of upstream Chinese medicinal materials, it is expected that the industry price increase is expected to be implemented in 2022, and the estimated price increase is 10%-30%
.
From the perspective of corporate gross profit margin, most of the top Chinese patent medicine OTC companies have established their own planting bases, which are less affected by the price increase of upstream Chinese herbal medicines and the control of medical insurance costs.
Ability and terminal premium ability are strong
.
The industry believes that, benefiting from the clearing of industry production capacity and the increase in terminal prices, the advantages of giant companies are prominent, and the industry concentration has increased
.
In recent years, new Chinese medicines have been favored by the acceleration of review and approval, and the speed and number of approvals for marketing have changed a lot
.
The number of innovative traditional Chinese medicine drugs approved in 2021 has reached 12, and in 2022, a new anti-cancer drug, icariin soft capsule, has also been approved for marketing
.
The industry expects that in the next few years, the number of new Chinese medicines approved each year will remain above 10
.
From the perspective of payment, in the medical insurance negotiation in recent years, the proportion of traditional Chinese medicines included in medical insurance has been increasing year by year
.
At the same time, in 2021, the state will also provide guidance on TCM medical institutions and the inclusion of traditional Chinese medicine medical insurance, etc.
, and pointed out that TCM medical institutions may not implement DRG payment for the time being
.
The industry believes that the inflection point of new traditional Chinese medicine drugs has reached, and it is expected to be included in the medical insurance first to achieve heavy volume
.
Compared with traditional decoction pieces, traditional Chinese medicine formula granules have the advantages of convenient taking, convenient carrying and storage,
etc.
The pilot work of traditional Chinese medicine formula granules was officially announced in November 2021, and the ten billion market has ushered in opportunities and challenges.
The industry believes that the future expansion of the traditional Chinese medicine formula market is expected to accelerate, and the filing system and the new national standard will build high industry barriers
.
Without considering the influence of factors such as centralized procurement, it is estimated that the market size of traditional Chinese medicine formula granules will reach 64-108 billion yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
